Stimulant Drugs Prove Useful for Children with ADHD and Tourette Syndrome

Stimulant medications are increasingly gaining credibility for being a safe and effective option for ADHD (Attention Deficit Hyperactivity Disorder) treatment as far as children are concerned. Improved formulations of stimulants have benefitted children in letting them focus their thoughts better and ignore distractions. Companies in the controlled substance market are teaming up with doctors and healthcare providers to combine the treatment of stimulant medications with behavior therapy to treat children suffering from ADHD. This developmental aspect has helped children pay more attention to routine activities and control their behavior.

The application of stimulants in the treatment of ADHD is estimated to increase in the coming years. ADHD accounts for the second-highest revenue amongst all applications in the controlled substance market, with a projected value of ~US$ 25 billion by the end of 2027. Due to these favorable aspects, it has been found that, the right medication of stimulants amongst ADHD patients has shown positive improvements in their behavioral patterns. Two forms of stimulants, namely, immediate release (short-acting) medications and extended release (immediate-acting and long-acting) medications are lately being talked about in the controlled substance market. The former is gaining increased popularity, since the medication is less expensive as compared to other stimulant drugs.

Stimulant drugs are even proving useful for patients with Tourette syndrome. Medications such as atomoxetine or guanfacine are safe and recommended for children to reduce conditions associated with frequent tics and unusual vocal sounds.

controlled substance market infographic

Request a sample to get extensive insights into the Controlled Substance Market

Pain Management Increases Scope of Opioid Treatment for Advanced Cancer Patients

Pain management is a necessary aspect for patients associated with advanced cancer. Thus, opioids are highly recommended for cancer patients to reduce the discomfort caused due to a diverse group of pain syndromes. Pain management is estimated to account for the highest revenue amongst all applications in the controlled substance market, with an estimated value of ~US$ 43 billion by the end of 2027. Thus, the increased prescription of opioid for advanced cancer patients is one of the major reasons for the exponential growth of pain management in the controlled substance market.

Although opioids help reduce the severity of pain syndromes, certain drawbacks of the medication are leading to resistance in its adoption amongst advanced cancer patients. Cognitive impairment and delirium are some of the few side effects caused due to the consumption of opioids. To overcome these drawbacks, healthcare companies in the controlled substance market are increasing awareness about screening in the early stages of delirium. Mini Mental State Examination and the Memorial Delirium-Assessment Scale are some of the credible tools that aid the screening procedure to assess the severity of cognitive impairment and delirium in patients.

In order to encourage advanced cancer patients to adopt opioids, companies in the controlled substance market are educating doctors and healthcare providers to thoroughly examine the complex and multi-faceted nature of pain management amongst patients.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Judicious Prescription of Tramadol to Reduce Incidence of Morbidity and Mortality

The controlled substance market is projected to grow at a healthy CAGR of ~7% during the forecast period. However, on the other hand, the limitations and adverse effects of certain drugs may hamper the growth of the controlled substance market. For instance, tramadol is an effective drug for pain relief, but confounding reasons of patients have led to instances of increased morbidity and mortality.

Tramadol has the potential for abuse and addiction. Although tramadol is being utilized and accepted in medical care, it is tightly regulated. Confounding reasons present ambiguity for the effectiveness of tramadol. Although tramadol is classified as a Schedule IV drug, lack of appropriate prescription for the drug has caused high rates of death in the controlled substance landscape. To overcome these challenges, manufacturers in the controlled substance market are increasing awareness about the judicious prescription of tramadol. They are increasing research & development to help educate doctors and patients about the potential risks of tramadol treatment.

In order to make medical research studies more authentic, companies in the controlled substance market should assess confounders to enhance the credibility of research outcomes. Healthcare companies are increasing the availability of tramadol amongst patients suffering from osteoarthritis and other painful conditions.  

controlled substance market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Controlled Substance Market” 

Analysts’ Viewpoint

Opioids are efficacious pain-reducing medications. However, strict laws and regulations dictate the prescription of opioids, since these medications are found to cause serious harm to patients, owing to their side effects. As such, healthcare companies need to work in collaboration with health commissions such as the FDA to improve enforcement on the illicit marketing of unapproved opioids, and offer access to improved treatment alternatives for patients suffering from acute and chronic pain.

Manufacturers should strengthen their distribution networks through retail and online pharmacies, as these two sectors are projected for high growth in the controlled substance market. Likewise, there is scope for increased market growth in Europe and Asia Pacific, owing to improvements in the healthcare infrastructure in both these regions.

Global Controlled Substance Market: Description

  • Controlled substances are drugs or chemicals that are controlled under the Controlled Substance Act (CSA). The manufacture, possession, or use of these drugs is regulated by a government. These are illegal drugs that can have a detrimental effect on a person's health and welfare. As a result, federal and state governments have regulated these substances. However, if someone has properly prescribed and lawfully purchased one of these substances, they are exempted from prosecution.
  • These substances are used for assistance in the treatment of several types of neurological disorders, as well as in drug research.
  • The demand for controlled substances has been increasing due to the rise in the number of people suffering from various ailments, such as chronic pain. Drugs such as opioids are the most effective analgesics for severe pain, and the mainstay of acute and terminal cancer pain treatments. The development of existing controlled substance molecules in different dosages is boosting their demand in the prescription market. For instance, amphetamine chewable tablets in various formulations create the demand for controlled substances to treat diseases such as ADHD, which affects millions of children across the world.
  • The global controlled substance market was valued at ~US$ 64 Bn in 2018, and is projected to reach a value of ~US$ 115 Bn by 2027, expanding at a CAGR of ~7% during the forecast period of 2019 to 2027.

Controlled Substance Market: Drivers

  • The high incidence rate of chronic pain among the geriatric population across the globe is one of the factors that increases the demand for the use of controlled substances. Several categories of pain medications are available; opioid analgesics are FDA-approved for moderate to severe pain, and effectively work in pain management.
  • The high rate of attention deficit hyperactivity disorder (ADHD) among children is putting more pressure for new drug formulations based on controlled substances. This is creating growth opportunities for controlled drugs, such as opioids and stimulants, in the controlled substance market.
  • The introduction of new products would expand the controlled substance market, while providing more options for effective treatment. Drugs such as amphetamine, in high concentration, that are available in the market in different forms, can be easily addictive if taken for a long time, especially by adolescents. Several pharmaceutical companies are taking efforts to push in new products based on controlled substances in the market, to provide better treatment options with low concentration to people who suffer from diseases such as sleep disorder and ADHD. For instance, in 2016, Neos Therapeutics Inc. launched a new candy-flavored amphetamine chewable tablet in the controlled substance market to treat ADHD patients.
  • Oxycodone exhibits better analgesic efficacy than fentanyl, and comparable efficacy to morphine. In terms of patient satisfaction, higher satisfaction levels were observed with oxycodone in different studies, which has resulted in increased sales across the globe.
  • Amphetamine IR and ER formulation development is one major trend observed, which shows promising growth in the next few years due to a number of upcoming launches by several players for specific indications.
  • Overall growth of the controlled substance market can be ascribed to rise in the prevalence of diseases which need controlled substances to treat them. Hence, overall increase in the patient pool has led to growth of the global controlled substance market.
  • New product approvals such as cocaine-based, C-Topical solutions or upcoming launches such as intranasal fentanyl sprays for cancer pain are some of the evolving trends in this industry, and can be growing factors for the overall controlled substance market.

Global Controlled Substance Market: Prominent Segments

  • Rise in attention deficit hyperactivity disorder prevalence and recently launched products in this category are some of the major factors expected to drive the ADHD segment in the global controlled substance market in terms of application.
  • Based on distribution channel, the retail pharmacies segment is likely to be a highly lucrative segment during the forecast period, owing to a rise in the number of retail pharmacies, especially in the Asia Pacific region.

Global Controlled Substance Market: Competition Landscape

  • Key players analyzed in this report on the global controlled substance market are -
    • F. Hoffmann-La Roche AG
    • AbbVie, Inc.
    • Mallinckrodt plc
    • Pfizer, Inc.
    • Sun Pharmaceuticals Ltd.
    • Ampac Fine Chemicals
    • GW Pharmaceuticals plc
    • Merck & Co., Inc.
    • Lannett
    • Teva Pharmaceutical Ltd.
  • Each of these players in the controlled substance market have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
  • Strategic mergers & acquisitions, new product launches, and emphasis on research & development are some of the key strategies adopted by major players in the global controlled substance market.
    • For instance, in 2016, Teva Pharmaceuticals Ltd. acquired Activis Pharma, an Ireland-based leading opioid manufacturer, to increase its presence in the controlled substance market.
    • In December, 2017, Genus Lifesciences, Inc., received FDA approval for its product - GOPRELTO nasal solution, 4% (cocaine hydrochloride), for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.

Controlled Substance Market – Scope of the Report

TMR’S report on the global controlled substance market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global controlled substance market for the period of 2017 - 2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global controlled substance market for the forecast period.

The controlled substance market report has been prepared after extensive primary and secondary research. Primary research involves bulk of the research efforts, wherein, analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global controlled substance market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approach to study various phenomena in the global controlled substance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study of the controlled substance market. Furthermore, the report sheds light on the changing competitive dynamics in the global controlled substance market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global controlled substance market.

The report delves into the competitive landscape of the global controlled substance market. Key players operating in the global controlled substance market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global controlled substance market that have been profiled in this report.

Key Questions Answered in the Controlled Substance Market Report

  1. What is the sales/revenue generated by each drug across all regions in the controlled substance market during the forecast period?
  2. What are the opportunities in the global controlled substance market?
  3. What are the major drivers, restraints, opportunities, and threats in the controlled substance market?
  4. Which region is likely to expand at the fastest CAGR in the global controlled substance market during the forecast period?
  5. Which controlled substance drug and application segments are expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  6. What was the market share or position of different companies operating in the global controlled substance market in 2018?

Global Controlled Substance Market – Research Objectives and Research Approach

The comprehensive report on the global controlled substance market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides a detailed explanation of the objectives behind this study, regulatory scenario, pipeline analysis of upcoming different scheduled drugs for medical use, and key mergers & acquisitions to combat in the market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows the comparison of the market shares of key segments in the past and at the end of the forecast period.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Global Controlled Substance Market - Segmentation

TMR’s study on the global controlled substance market includes information divided into four sections - drug, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global controlled substance market have been discussed in detail.

Drug

  • Opioids
  • Stimulants
  • Depressants
  • Cannabinoids

Application

  • ADHD
  • Pain Management
  • Depression
  • Sleep Disorder
  • Cough Suppression
  • Anxiety
  • Seizure
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Controlled Substance Market

4. Market Overview

    4.1. Introduction

        4.1.1. Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Controlled Substance Market Analysis and Forecasts, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Key Merger & Acquisition

    5.3. Regulatory Scenario

6. Global Controlled Substance Market Analysis and Forecasts, by Drug, 2017-2027 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug, 2017–2027

        6.3.1. Opioids

            6.3.1.1. Codeine

            6.3.1.2. Morphine

            6.3.1.3. Fentanyl

            6.3.1.4. Hydrocodone

            6.3.1.5. Tramadol

            6.3.1.6. Oxycodone

            6.3.1.7. Others

        6.3.2. Stimulants

            6.3.2.1. Amphetamine

            6.3.2.2. Methylphenidate

            6.3.2.3. Dextroamphetamine

            6.3.2.4. Methamphetamine

            6.3.2.5. Modafinil

            6.3.2.6. Others

        6.3.3. Depressants

            6.3.3.1. Barbiturates

            6.3.3.2. Benzodiazepines

        6.3.4. Cannabinoids

    6.4.  Market Attractiveness, by Drug 

7. Global Controlled Substance Market Analysis and Forecasts, by Application, 2017-2027 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2027

        7.3.1. ADHD

        7.3.2. Pain Management

        7.3.3. Depression

        7.3.4. Sleep Disorder

        7.3.5. Cough Suppression

        7.3.6. Anxiety

        7.3.7. Seizure

        7.3.8. Others

    7.4.  Market Attractiveness, by Application 

8. Global Controlled Substance Market Analysis and Forecasts, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Application

9. Global Controlled Substance Market Analysis and Forecasts, by Region, 2017-2027

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Controlled Substance Market Analysis and Forecast, 2017-2027

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug, 2017–2027

        10.2.1. Opioids

            10.2.1.1. Codeine

            10.2.1.2. Morphine

            10.2.1.3. Fentanyl

            10.2.1.4. Hydrocodone

            10.2.1.5. Tramadol

            10.2.1.6. Oxycodone

            10.2.1.7. Others

        10.2.2. Stimulants

            10.2.2.1. Amphetamine

            10.2.2.2. Methylphenidate

            10.2.2.3. Dextroamphetamine

            10.2.2.4. Methamphetamine

            10.2.2.5. Modafinil

            10.2.2.6. Others

        10.2.3. Depressants

            10.2.3.1. Barbiturates

            10.2.3.2. Benzodiazepines

        10.2.4. Cannabinoids

    10.3. Market Value Forecast, by Application, 2017-2027

        10.3.1. ADHD

        10.3.2. Pain Management

        10.3.3. Depression

        10.3.4. Sleep Disorder

        10.3.5. Cough Suppression

        10.3.6. Anxiety

        10.3.7. Seizure

        10.3.8. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017-2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017-2027 

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug 

        10.6.2. By Application 

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Controlled Substance Market Analysis and Forecast, 2017-2027

    11.1. Introduction

        11.1.1. Key Finding

    11.2. Market Value Forecast, by Drug, 2017-2027

        11.2.1. Opioids

            11.2.1.1. Codeine

            11.2.1.2. Morphine

            11.2.1.3. Fentanyl

            11.2.1.4. Hydrocodone

            11.2.1.5. Tramadol

            11.2.1.6. Oxycodone

            11.2.1.7. Others

        11.2.2. Stimulants 

            11.2.2.1. Amphetamine

            11.2.2.2. Methylphenidate

            11.2.2.3. Dextroamphetamine

            11.2.2.4. Methamphetamine

            11.2.2.5. Modafinil

            11.2.2.6. Others

        11.2.3. Depressants

            11.2.3.1. Barbiturates

            11.2.3.2. Benzodiazepines

        11.2.4. Cannabinoids

    11.3. Market Value Forecast, by Application, 2017-2027

        11.3.1. ADHD

        11.3.2. Pain Management

        11.3.3. Depression

        11.3.4. Sleep Disorder

        11.3.5. Cough Suppression

        11.3.6. Anxiety

        11.3.7. Seizure

        11.3.8. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017-2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017-2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug 

        11.6.2. By Application 

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Controlled Substance Market Analysis and Forecast, 2017-2027

    12.1. Introduction

        12.1.1. Key Finding

    12.2. Market Value Forecast, by Drug, 2017-2027

        12.2.1. Opioids

            12.2.1.1. Codeine

            12.2.1.2. Morphine

            12.2.1.3. Fentanyl

            12.2.1.4. Hydrocodone

            12.2.1.5. Tramadol

            12.2.1.6. Oxycodone

            12.2.1.7. Others

        12.2.2. Stimulants 

            12.2.2.1. Amphetamine

            12.2.2.2. Methylphenidate

            12.2.2.3. Dextroamphetamine

            12.2.2.4. Methamphetamine

            12.2.2.5. Modafinil

            12.2.2.6. Others

        12.2.3. Depressants

            12.2.3.1. Barbiturates

            12.2.3.2. Benzodiazepines

        12.2.4. Cannabinoids 

    12.3. Market Value Forecast, by Application, 2017-2027

        12.3.1. ADHD

        12.3.2. Pain Management

        12.3.3. Depression

        12.3.4. Sleep Disorder

        12.3.5. Cough Suppression

        12.3.6. Anxiety

        12.3.7. Seizure

        12.3.8. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017-2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017-2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug 

        12.6.2. By Application 

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Controlled Substance Market Analysis and Forecast, 2017-2027

    13.1. Introduction

        13.1.1. Key Finding

    13.2. Market Value Forecast, by Drug, 2017-2027

        13.2.1. Opioids

            13.2.1.1. Codeine

            13.2.1.2. Morphine

            13.2.1.3. Fentanyl

            13.2.1.4. Hydrocodone

            13.2.1.5. Tramadol

            13.2.1.6. Oxycodone

            13.2.1.7. Others

        13.2.2. Stimulants 

            13.2.2.1. Amphetamine

            13.2.2.2. Methylphenidate

            13.2.2.3. Dextroamphetamine

            13.2.2.4. Methamphetamine

            13.2.2.5. Modafinil

            13.2.2.6. Others

        13.2.3. Depressants

            13.2.3.1. Barbiturates

            13.2.3.2. Benzodiazepines

        13.2.4. Cannabinoids

    13.3. Market Value Forecast, by Application, 2017-2027

        13.3.1. ADHD

        13.3.2. Pain Management

        13.3.3. Depression

        13.3.4. Sleep Disorder

        13.3.5. Cough Suppression

        13.3.6. Anxiety

        13.3.7. Seizure

        13.3.8. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017-2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast by Country/Sub-region, 2017-2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug 

        13.6.2. By Application 

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Controlled Substance Market Analysis and Forecast, 2017-2027

    14.1. Introduction

        14.1.1. Key Finding

    14.2. Market Value Forecast, by Drug, 2017-2027

        14.2.1. Opioids

            14.2.1.1. Codeine

            14.2.1.2. Morphine

            14.2.1.3. Fentanyl

            14.2.1.4. Hydrocodone

            14.2.1.5. Tramadol

            14.2.1.6. Oxycodone

            14.2.1.7. Others

        14.2.2. Stimulants 

            14.2.2.1. Amphetamine

            14.2.2.2. Methylphenidate

            14.2.2.3. Dextroamphetamine

            14.2.2.4. Methamphetamine

            14.2.2.5. Modafinil

            14.2.2.6. Others

        14.2.3. Depressants

            14.2.3.1. Barbiturates

            14.2.3.2. Benzodiazepines

        14.2.4. Cannabinoids 

    14.3. Market Value Forecast, by Application, 2017-2027

        14.3.1. ADHD

        14.3.2. Pain Management

        14.3.3. Depression

        14.3.4. Sleep Disorder

        14.3.5. Cough Suppression

        14.3.6. Anxiety

        14.3.7. Seizure

        14.3.8. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017-2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017-2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Drug 

        14.6.2. By Application 

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Position/Ranking Analysis by Company (2018)

    15.3. Company Profiles

        15.3.1. F. Hoffmann-La Roche AG

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. AbbVie, Inc.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Mallinckrodt plc

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Pfizer, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Sun Pharmaceutical Ltd.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Ampac Fine Chemicals

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. GW Pharmaceuticals plc

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Merck & Co., Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

List of Tables

Table 01: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 02: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 03: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 04: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 05: Global Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 06: Global Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 07: Global Controlled Substance Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Controlled Substance Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 10: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 11: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 12: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 13: North America Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 14: North America Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 16: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 17: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 18: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 19: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 20: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 21: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 22: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 23: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 24: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 25: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 26: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 27: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 28: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 29: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 30: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 31: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 32: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 33: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 34: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 35: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 36: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 37: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 38: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

Table 39: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

Table 40: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

Table 41: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 42: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Controlled Substance Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Market Opportunity Map, by Drug Type, 2018

Figure 03: Global Controlled Substance Market Value (US$ Mn) Forecast, 2017–2027

Figure 04: Global Controlled Substance Market Value Share, by Drug (2018)

Figure 05: Global Controlled Substance Market Value Share, by Application (2018)

Figure 06: Global Controlled Substance Market Value Share, by Distribution Channels (2018)

Figure 07: Global Controlled Substance Market Value Share, by Region (2018)

Figure 08: Global Controlled Substance Market Value Share Analysis, by Drug, 2018 and 2027

Figure 09: Global Controlled Substance Market Revenue (US$ Mn) by Opioids, 2017-2027

Figure 10: Global Controlled Substance Market Revenue (US$ Mn) by Stimulants, 2017-2027

Figure 11: Global Controlled Substance Market Revenue (US$ Mn) by Depressants, 2017-2027

Figure 12: Global Controlled Substance Market Revenue (US$ Mn) by Cannabinoids, 2017-2027

Figure 13: Global Controlled Substance Market Attractiveness Analysis, by Drug, 2019–2027

Figure 14: Global Controlled Substance Market Value Share Analysis, by Application, 2018 and 2027

Figure 15: Global Controlled Substance Market Value (US$ Mn), by ADHD, 2017–2027

Figure 16: Global Controlled Substance Market Value (US$ Mn), by Pain Management, 2017–2027

Figure 17: Global Controlled Substance Market Value (US$ Mn), by Depression, 2017–2027

Figure 18: Global Controlled Substance Market Value (US$ Mn), by Sleep Disorder, 2017–2027

Figure 19: Global Controlled Substance Market Value (US$ Mn), by Cough Suppression, 2017–2027

Figure 20: Global Controlled Substance Market Value (US$ Mn), by Anxiety, 2017–2027

Figure 21: Global Controlled Substance Market Value (US$ Mn), by Seizure, 2017–2027

Figure 22: Global Controlled Substance Market Value (US$ Mn), by Others, 2017–2027

Figure 23: Global Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 24: Global Controlled Substance Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 25: Global Controlled Substance Market Revenue (US$ Mn) by Hospital Pharmacies, 2017-2027

Figure 26: Global Controlled Substance Market Revenue (US$ Mn) Retail Pharmacies, 2017-2027

Figure 27: Global Controlled Substance Market Revenue (US$ Mn) Online Pharmacies, 2017-2027

Figure 28: Global Controlled Substance Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 29: Global Controlled Substance Market Value Share Analysis, by Region, 2018 and 2027

Figure 30: Global Controlled Substance Market Attractiveness Analysis, by Region, 2019–2027

Figure 31: North America Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 32: North America Controlled Substance Market Value Share, by Country, 2018 and 2027

Figure 33: North America Controlled Substance Market Attractiveness, by Country, 2019–2027

Figure 34: North America Controlled Substance Market Value Share, by Drug, 2018 and 2027

Figure 35: North America Controlled Substance Market Attractiveness, by Drug, 2019–2027

Figure 36: North America Controlled Substance Market Value Share, by Application, 2018 and 2027

Figure 37: North America Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 38: North America Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

Figure 39: North America Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

Figure 40: Europe Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 41: Europe Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 42: Europe Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 43: Europe Controlled Substance Market Value Share, by Drug, 2018 and 2027

Figure 44: Europe Controlled Substance Market Attractiveness, by Drug, 2019–2027

Figure 45: Europe Controlled Substance Market Value Share, by Application, 2018 and 2027

Figure 46: Europe Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 47: Europe Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

Figure 48: Europe Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

Figure 49: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 50: Asia Pacific Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 51: Asia Pacific Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 52: Asia Pacific Controlled Substance Market Value Share, by Drug, 2018 and 2027

Figure 53: Asia Pacific Controlled Substance Market Attractiveness, by Drug, 2019–2027

Figure 54: Asia Pacific Controlled Substance Market Value Share, by Application, 2018 and 2027

Figure 55: Asia Pacific Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 56: Asia Pacific Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

Figure 57: Asia Pacific Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

Figure 58: Latin America Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 59: Latin America Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 60: Latin America Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 61: Latin America Controlled Substance Market Value Share, by Drug, 2018 and 2027

Figure 62: Latin America Controlled Substance Market Attractiveness, by Drug, 2019–2027

Figure 63: Latin America Controlled Substance Market Value Share, by Application, 2018 and 2027

Figure 64: Latin America Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 65: Latin America Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

Figure 66: Latin America Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

Figure 67: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 68: Middle East & Africa Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 69: Middle East & Africa Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 70: Middle East & Africa Controlled Substance Market Value Share, by Drug, 2018 and 2027

Figure 71: Middle East & Africa Controlled Substance Market Attractiveness, by Drug, 2019–2027

Figure 72: Middle East & Africa Controlled Substance Market Value Share, by Application, 2018 and 2027

Figure 73: Middle East & Africa Controlled Substance Market Attractiveness, by Application, 2019–2027

Figure 74: Middle East & Africa Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

Figure 75: Middle East & Africa Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

Figure 76: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Controlled Substances Market